Skip to main content

Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other
Gupta, S; Halabi, S; Yang, Q; Roy, A; Tubbs, A; Gore, Y; George, DJ; Nanus, DM; Antonarakis, ES; Danila, DC; Szmulewitz, RZ; Wenstrup, R ...
April 12, 2023

<p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subjects at baseline, by RECIST 1.1 criteria.</p>

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

DOI

Publication Date

April 12, 2023
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gupta, S., Halabi, S., Yang, Q., Roy, A., Tubbs, A., Gore, Y., … Armstrong, A. J. (2023). Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. https://doi.org/10.1158/1078-0432.22596021
Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” April 12, 2023. https://doi.org/10.1158/1078-0432.22596021.
Gupta S, Halabi S, Yang Q, Roy A, Tubbs A, Gore Y, George DJ, Nanus DM, Antonarakis ES, Danila DC, Szmulewitz RZ, Wenstrup R, Armstrong AJ. Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. 2023.

DOI

Publication Date

April 12, 2023